Oral Drug Delivery Videos

  1. Management Responsibility and the New QMSR 7/11/2024

    What is management’s responsibility in the implementation of approaches to the new QMSR? In this segment of the Drug Delivery Leader Live event New FDA QMSR: Its Role in Part 4 Compliance for Combination Products, consultant Laurie Auerbach of Compliance Prodigies underscores the criticality of management commitment to and engagement in the process.

  2. Oral Drug Delivery For Breast Cancer Prevention With Atossa Therapeutics' Steven Quay 4/7/2025

    In this episode of Sit and Deliver, host Tom von Gunden talks with Atossa Therapeutics CEO Steven Quay about oral drug delivery for early intervention in patients at high risk of breast cancer. The discussion covers formulations, coatings, and dosing for orally administered, cancer-preventative approaches to reducing breast density. 

  3. Technology To Overcome Absorption Hurdles And Solubility Limitations 3/6/2024

    For poorly soluble drugs, overcoming absorption hurdles can hinder development. Explore a solution that empowers researchers to overcome solubility limitations and accelerate drug development.

  4. Partnership And Clinical Trial Strategies For Digitally Connected Devices 5/23/2025

    In this segment of the Drug Delivery Leader Live online event, Innovations In Drug Delivery: Opportunities For Enhancing Familiar, Mature Approaches, James Wabby, head of global regulatory affairs for emerging device technologies and combination products at AbbVie, and Carolyn Dorgan, director of technical services at device design consultancy Suttons Creek, discuss key product development considerations when bringing digital connectivity solutions to drug delivery devices. These aspects include product and health authority partnerships, clinical studies, and regulatory approvals.

  5. Developing Therapy Delivery Options For Autoimmune And Allergic Diseases At Revolo Biotherapeutics 4/22/2025

    In this episode of In Combination, host Tom von Gunden combines the perspectives of three executives at Revolo Biotherapeutics – CEO Woody Bryan, Chief Scientific Officer Roly Foulkes, and Chief Medical Officer Kari Brown – in a discussion about developing and delivering peptide-based alternatives to steroids for allergic and autoimmune diseases.

  6. Improve The Bioavailability Of Poorly Soluble Drugs 3/19/2024

    KinetiSol is a fusion-based, solvent-free process that utilizes frictional and shear energies — in a fraction of the time of other amorphous solid dispersion technologies.

  7. Charting The Waters Of Drug Delivery Innovation With Suttons Creek 7/11/2025

    In this episode of In Combination, the technical leadership team from device consultancy Suttons Creek joins host Tom von Gunden to discuss trends in the patient landscape driving innovation in drug delivery, including combination products and therapies. The conversation covers patient self-administration, emerging modalities, and key considerations in product development, regulatory pathways, and the supply chain.

  8. Taste Masking 101: Sensory And Performance Evaluation 7/11/2022

    Learn how techniques and innovations in taste masking sensory and performance evaluation can help accelerate your formulation development and confirm desired taste profile.

  9. Solid Form Screening Of Active Pharmaceutical Ingredients

    Explore the role of solid form services in helping meet accelerated timelines of the drug development lifecycle along with examples of robust workflows for fast and thorough solid form screens.

  10. Understanding How EDDOs Relate To CGMPs 4/23/2025

    How are EDDOs (Essential Drug Delivery Outputs) related to CGMPs (Current Good Manufacturing Practices) during the design of a drug-led or biologic-led combination product? In this segment of the Drug Delivery Leader Live event EDDOs Revisited: Putting Essential Drug Delivery Outputs Into Practice, consultant Susan Neadle of Combination Products Consulting Services, LLC establishes the connection between the two regulatory concepts.